Jonathan Li, MD
Enriched profileAssociate Professor of Medicine, Harvard Medical School; Physician, Division of Infectious Diseases, Brigham and Women's Hospital · Brigham and Women's Hospital
Jonathan Li is Associate Professor of Medicine, Harvard Medical School; Physician, Division of Infectious Diseases, Brigham and Women's Hospital at Brigham and Women's Hospital. OpenAlex indexes 331 publications with 17,418 citations (h-index 59); ClinicalTrials.gov lists 3 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Infectious Disease profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Jonathan Z. Li, MD, is Associate Professor of Medicine, Harvard Medical School at Brigham and Women's Hospital / Harvard Medical School. The public record shows 331 publications with 17,418 citations (h-index 59), centered on SARS-CoV-2 and COVID-19 Research, HIV Research and Treatment, COVID-19 Clinical Research Studies. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 8 companies, 12 NIH-funded awards (2012–2026).
- Most recent indexed publication: 2026 · Microbiology spectrum
- Top research focus: SARS-CoV-2 and COVID-19 Research
- 3 registered trials on ClinicalTrials.gov
- Open Payments reporting from 8 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 43 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 179.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Member
NIH COVID-19 Treatment Guidelines Panel
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →actg-impaact-lc.org ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:
- Music Therapy for Oral Mucositis Pain in Pediatric Patients
Sponsor: University of California, San Francisco
- Biomarkers to Predict Time to Plasma HIV RNA Rebound
Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Industry payments
Updated 27 Aug 2026
8 companies reported payments to CMS in program years 2023–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202510 payments
- Shionogi IncProgram year20251 payment
- Gilead Sciences, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
36.4%Calcium channel blocker22.1%Amlodipine Besylate100%Part D<11 patientsStatin14.3%Atorvastatin Calcium100%Part D<11 patientsAnti-infectives
32.5%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor16.9%Tivicay100%Part D<11 patientsHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor15.6%Descovy100%Part D<11 patientsMetabolism & gastrointestinal
31.2%Sulfonylurea15.6%Glimepiride100%Part D<11 patientsDPP-4 inhibitor15.6%Tradjenta100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
12 NIH research awards on record, funded 2012–2026 per NIH RePORTER. The latest:
- High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir
Brigham and Women'S Hospital
FY2026$1,645,054P01AI169768 - High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Project 1
Brigham and Women'S Hospital
FY2026$461,151P01AI169768
Congress activity
Updated 27 Aug 2026
2 congress contributions (2019) across AACR per OpenAlex. The most recent:
- Abstract 1538: Margetuximab mediates greater Fc-dependent anti-tumor activities than trastuzumab or pertuzumab in vitro
AACR (meeting unresolved)
AACR2019Co-author - Abstract 1560: Selection of a bispecific trivalent HER2 x CD137 TRIDENT format providing optimal tumor-anchored immune co-stimulation
AACR (meeting unresolved)
AACR2019Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Effect of inhaled interferon-β1a on SARS-CoV-2 diversity and evolution.
Microbiology spectrum
Clinical Trial2026 - Expansion of stemlike HIV-specific CD8(+) T cells and limited viral epitope diversity characterize durable posttreatment control of HIV.
Science translational medicine
Article2026 - Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-elicited SARS-CoV-2 Immune Responses.
The Journal of infectious diseases
Article2026
Most-cited works
by citation count (OpenAlex)- 01Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host1,383 citations2020
- 02
- 03
- 04Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing805 citations2020
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mghbwhid.hms.harvard.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mghbwhid.hms.harvard.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →jonathanlilab.bwh.harvard.edu ↗
Editorial & leadership roles
journal and society appointments- Deputy Editor
Journal of Infectious Diseases
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →jonathanlilab.bwh.harvard.edu ↗ - Vice Chair
ACTG HIV Reservoirs and Eradication Transformative Science Group
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →jonathanlilab.bwh.harvard.edu ↗ - Member
AIDS Clinical Trials Group (ACTG) Executive Committee (former)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →actg-impaact-lc.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →jonathanlilab.bwh.harvard.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →jonathanlilab.bwh.harvard.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →jonathanlilab.bwh.harvard.edu ↗
Secondary affiliations
appointments beyond the home institution- Director
Harvard/Brigham Virology Specialty Laboratory
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →jonathanlilab.bwh.harvard.edu ↗ - Director
Harvard University Center for AIDS Research (CFAR) Clinical Core
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →jonathanlilab.bwh.harvard.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →jonathanlilab.bwh.harvard.edu ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →contagionlive.com ↗
- Featured researcher
"Finding HIV's last bastion in the body", Science Magazine Podcast
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Ridker, MD
Brigham and Women's Hospital
Scott Solomon, MD
Brigham and Women's Hospital
Dennis Selkoe, MD
Brigham and Women's Hospital
Marc Pfeffer, MD
Brigham and Women's Hospital